The latest report by IMARC Group, titled “India Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“, offers a comprehensive analysis of the industry, which comprises insights on the India generic injectables market growth. The market size reached US$ 2.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.9 Billion by 2028, exhibiting a growth rate (CAGR) of 12.4% during 2023-2028.

Generic injectables refer to alternative drugs that are bio-equivalent to branded drugs in terms of active ingredients, quality, strength, effectiveness, intended use, and dosage. They are used to treat various life-threatening and chronic illnesses, including cancer, diabetes, rheumatoid arthritis, cardiovascular diseases, and respiratory infections. Compared to innovator drugs, generic injectables provide improved patient compliance, reduced frequency of drug delivery, limited price erosion, and higher profitability for manufacturers. Since they deliver the same amount of active ingredients to the body and offer clinical benefits and therapeutic effects similar to their branded counterparts at much lower prices, generic injectables are gaining immense traction across India.

India Generic Injectables Market Size and Trends:

The India generic injectables market is primarily driven by the rising prevalence of chronic diseases, such as cancer, stroke, diabetes, septicemia, influenza, pneumonia, respiratory problems, and Alzheimer's disease. Moreover, rising investments in research and development (R&D) activities by the government of India to introduce innovative generic injectables and improve drug administration for faster patient recovery is positively influencing the market growth. Additionally, numerous technological advancements in drug delivery systems, such as the launch of self-injection devices, have catalyzed market growth. Furthermore, the introduction of 3D printing technology for manufacturing generic drugs with varying release dates and tastes is contributing to market growth. Other factors, including rapid expansion in the healthcare industry, the increasing shortage of branded medicines across the country, and upcoming patent expirations of branded drugs, are also anticipated to drive the market further.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/india-generic-injectables-market/requestsample

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Therapeutic Area:

• Oncology
• Anaesthesia
• Anti-infectives
• Parenteral Nutrition
• Cardiovascular 

Breakup by Container:

• Vials
• Ampoules
• Premix
• Prefilled Syringes 

Breakup by Distribution Channel:

• Hospitals
• Retail Pharmacy

Breakup by Region:

• North India
• West and Central India
• South India
• East India

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

Email: sales@imarcgroup.com

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA 

Follow us on Twitter: @imarcglobal